Antibacterial activity of phytochemicals isolated from Erythrina zeyheri against vancomycin-resistant enterococci and their combinations with vancomycin

被引:32
|
作者
Sato, M
Tanaka, H
Oh-Uchi, T
Fukai, T
Etoh, H
Yamaguchi, R
机构
[1] Asahi Univ, Sch Dent, Dept Oral Pathol, Gifu 5010296, Japan
[2] Meijo Univ, Fac Pharm, Dept Nat Prod Chem, Tempaku Ku, Nagoya, Aichi 4688503, Japan
[3] Toho Univ, Sch Pharmaceut Sci, Chiba 2748510, Japan
[4] Shizuoka Univ, Fac Agr, Lab Marine Biochem Sci, Shizuoka 4228529, Japan
[5] Asahi Univ, Sch Dent, Inst Radioisotope, Gifu 5010296, Japan
关键词
VRE; MRSA; erybraedin A; eryzerin C; vancomycin; FIC index;
D O I
10.1002/ptr.1556
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Six phytochemicals were isolated from the roots of Eiythrina zeyheri (Leguminosae) by repeated silica gel column chromatography using various eluting solvents. Extensive spectroscopic studies revealed that all were isoflavonoids. The antibacterial activity of the six compounds against vancomycin-resistant enterococci (VRE) was estimated by determining the minimum inhibitory concentration (MIC). Of the six isoflavonoids, erybraedin A ((6aR, 11aR)-3,9-dihydroxy-4,10-di(gamma,gamma-dimethylallyl)pterocarpan) exhibited the highest growth inhibitory potency against VRE with an MIC value of 1.56-3.13 mug/mL, followed by eryzerin C ((3R)-7,2',4'-trihydroxy-6,8-di(gamma,gamma-dimethylailyl)isoflavan) (MIC 6.25 mug/mL). These compounds also inhibited the growth of methicillin-resistant Staphylococcus aureus (MRSA) at 3.13-6.25 mug/mL. The antibacterial effects of the two compounds against VRE and MRSA were based on bacteriostatic action. When erybraedin A or eryzerin C was combined with vancomycin, the fractional inhibitory concentration (FIC) index against VRE ranged from 0.5306 to 1.0 and from 0.5153 to 0.75, respectively. The combinations also showed FIC indices of 0.6125-1.0 against MRSA. The results indicate that, depending on the case, both compounds act either synergistically or additively with vancomycin against VRE and MRSA. Erybraedin A and eryzerin C show evidence of being potent phytotherapeutic agents against infections caused by VRE and MRSA. Copyright (C) 2004 John Wiley Sons, Ltd.
引用
收藏
页码:906 / 910
页数:5
相关论文
共 50 条
  • [31] In Vitro Activity of LY333328, a New Glycopeptide, against Extracellular and Intracellular Vancomycin-Resistant Enterococci
    B. Al-Nawas
    J. Swantes
    P. M. Shah
    Infection, 2000, 28 : 214 - 218
  • [32] Peptide/β-Peptoid Hybrids with Activity against Vancomycin-Resistant Enterococci: Influence of Hydrophobicity and Structural Features on Antibacterial and Hemolytic Properties
    Vestergaard, Martin
    Skive, Bolette
    Domraceva, Ilona
    Ingmer, Hanne
    Franzyk, Henrik
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (11)
  • [33] Vancomycin-resistant staphylococci and enterococci: epidemiology and control
    Tenover, FC
    McDonald, LC
    CURRENT OPINION IN INFECTIOUS DISEASES, 2005, 18 (04) : 300 - 305
  • [34] Importance of the structure of vancomycin binding pocket in designing compounds active against vancomycin-resistant enterococci (VRE)
    Jia, Yanxing
    Bois-Choussy, Michele
    Malabarba, Adriano
    Brunati, Cristina
    Zhu, Jieping
    JOURNAL OF ANTIBIOTICS, 2006, 59 (09) : 543 - 552
  • [35] Neocitreamicins I and II, Novel Antibiotics with Activity against Methicillin-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococci
    Aaron J Peoples
    Qibo Zhang
    William P Millett
    Mithra T Rothfeder
    Brian C Pescatore
    Anne A Madden
    Losee L Ling
    Charles M Moore
    The Journal of Antibiotics, 2008, 61 : 457 - 463
  • [36] Neocitreamicins I and II, novel antibiotics with activity against methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci
    Peoples, Aaron J.
    Zhang, Qibo
    Millett, William P.
    Rothfeder, Mithra T.
    Peseatore, Brian C.
    Madden, Anne A.
    Ling, Losee L.
    Moore, Charles M.
    JOURNAL OF ANTIBIOTICS, 2008, 61 (07) : 457 - 463
  • [37] Activity of vancomycin combined with linezolid against clinical vancomycin-resistant Enterococcus strains
    Aktas, Gulseren
    ARCHIVES OF MEDICAL SCIENCE, 2023, 19 (01) : 189 - 193
  • [38] Importance of the Structure of Vancomycin Binding Pocket in Designing Compounds Active Against Vancomycin-resistant Enterococci (VRE)
    Yanxing Jia
    Michèle Bois-choussy
    Adriano Malabarba
    Cristina Brunati
    Jieping Zhu
    The Journal of Antibiotics, 2006, 59 : 543 - 552
  • [39] Lipophilic vancomycin aglycon dimer with high activity against vancomycin-resistant bacteria
    Yarlagadda, Venkateswarlu
    Sarkar, Paramita
    Manjunath, Goutham B.
    Haldar, Jayanta
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2015, 25 (23) : 5477 - 5480
  • [40] Vancomycin modified copper sulfide nanoparticles for photokilling of vancomycin-resistant enterococci bacteria
    Zou, Zhonghao
    Sun, Jie
    Li, Qing
    Pu, Yang
    Liu, Jiaqi
    Sun, Ruiqi
    Wang, Luyao
    Jiang, Tingting
    COLLOIDS AND SURFACES B-BIOINTERFACES, 2020, 189